First Foundation Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

First Foundation Advisors’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.9M	Buy	3,052 +1	+0%	+$681	0.07%	146
2026 Q1	$2.36M	Buy	3,051 +2	+0.1%	+$1.53K	0.09%	132
2025 Q4	$2.35M	Hold	3,049	–	–	0.09%	129
2025 Q3	$1.71M	Sell	3,049 -4	-0.1%	-$2.26K	0.06%	145
2025 Q2	$1.6M	Sell	3,053 -50	-2%	-$27.9K	0.06%	153
2025 Q1	$1.97M	Buy	3,103 +4	+0.1%	+$2.75K	0.08%	127
2024 Q4	$2.21M	Sell	3,099 -10	-0.3%	-$8.39K	0.08%	117
2024 Q3	$3.27M	Hold	3,109	–	–	0.12%	103
2024 Q2	$3.27M	Hold	3,109	–	–	0.12%	92
2024 Q1	$2.99M	Buy	3,109 +50	+2%	+$47.5K	0.12%	94
2023 Q4	$2.69M	Sell	3,059 -169	-5%	-$139K	0.12%	98
2023 Q3	$2.66M	Sell	3,228 -1	-0%	-$786	0.12%	102
2023 Q2	$2.32M	Sell	3,229 -138	-4%	-$106K	0.1%	123
2023 Q1	$2.77M	Buy	3,367 +66	+2%	+$49.8K	0.13%	108
2022 Q4	$2.38M	Buy	+3,301	New	+$2.44M	0.11%	113
2021 Q4	–	Sell	-2,422	Closed	-$1.47M	–	462
2021 Q3	$1.47M	Sell	2,422 -377	-13%	-$234K	0.05%	161
2021 Q2	$1.56M	Buy	2,799 +52	+2%	+$26.3K	0.06%	164
2021 Q1	$1.3M	Buy	2,747 +1,590	+137%	+$774K	0.06%	174
2020 Q4	$559K	Buy	+1,157	New	+$625K	0.02%	251

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

First Foundation Advisors's REGN Position: Q2 2026 in Review

First Foundation Advisors increased its Regeneron Pharmaceuticals (REGN) stake by 0.03% in Q2 2026, buying an estimated $681 and bringing the position to 3,052 shares worth $1.9M. The position accounts for 0.07% of the portfolio, ranked #146.

First Foundation Advisors first reported a position in REGN in Q4 2020 and has held it in 19 quarters since. The position peaked at $3.27M in Q3 2024. 1,336 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

First Foundation Advisors held 3,052 shares of Regeneron Pharmaceuticals worth $1.9M as of Q2 2026.
First Foundation Advisors bought 1 Regeneron Pharmaceuticals share in Q2 2026, an estimated $681.
Regeneron Pharmaceuticals made up 0.07% of First Foundation Advisors's portfolio in Q2 2026, its #146 holding.
First Foundation Advisors first reported a position in Regeneron Pharmaceuticals in Q4 2020 and has held it in 19 quarters since.
First Foundation Advisors's Regeneron Pharmaceuticals position peaked at $3.27M in Q3 2024.
1,336 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on First Foundation Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.